TNF Pharmaceuticals Inc.
TNFA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$41.91M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $41.91 Million |
|---|---|
| Enterprise Value | $40.78 Million |
| Earnings per Share | $-8.66 |
| Beta | 2.28 |
| Outstanding Shares | 8,059,559 |
Return
| Return on Equity | -49.57% |
|---|---|
| Return on Assets | -30.67% |
| Return on Invested Capital | -26.46% |
Valuation & Multiples
| P/E Ratio | -0.1 |
|---|---|
| PEG | -0.95 |
| Price to Sales | - |
| Price to Book Ratio | 2.6 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.45 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.06%▼ 9.88% |
|---|---|
| Total Invested | $3▼ 100.00% |
| Investors Holding | 1▼ 28.00% |
About TNF Pharmaceuticals Inc.
CEO: Howard Yeaton
mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the ...